Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07069725
PHASE1

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.

Official title: A Phase 1, Open-label Positron Emission Tomography Trial to Assess Changes in Liver Uptake of [68Ga]Ga-FAPI-46 Following Oral Administration of Single Doses of AZD2389 to Patients With Advanced Liver Fibrosis (PECHORA).

Key Details

Gender

All

Age Range

20 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2025-05-26

Completion Date

2026-05-26

Last Updated

2026-02-19

Healthy Volunteers

No

Interventions

DRUG

AZD2389

Doses of AZD2389 will be administrated orally

DIAGNOSTIC_TEST

PET scan and radioligand

PET scan and radioligand

Locations (2)

Research Site

Solna, Sweden

Research Site

Stockholm, Sweden